However, recent pharmacovigilance analyses from FAERS and VigiBase have produced mixed findings, with weak-to-moderate safety signals for depressive or suicide-related events observed for semaglutide but not for other GLP-1 RAs, such as liraglutide or tirzepatide [113,114]
Monitoring Protocol for Combined Use Gastrointestinal symptoms require active assessment during the first three months
This guide breaks down the coding and billing rules for GLP-1 medications and provides practical tips for clean claims and compliant reimbursement
Starting doses typically begin lower, around 2.5 mg per week, with gradual increases over several weeks to minimize gastrointestinal side effects such as nausea and vomiting
Eye examination before starting treatment is recommended
"This has been an evolution, to discover incretins with more appealing pharmacological properties," he said